FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | Sample | Privacy
Related Topics >> cold chain | vaccine manufacturing

Sea option becoming viable for drug shipments

Free Newsletter

FiercePharma Manufacturing provides must-know news and insight on the hardware and software tools used to automate pharmaceutical manufacturing. Sign up today to receive your FREE "insiders only" weekly pharma manufacturing industry briefing.



Tools

Trouble is brewing above. Though beleaguered airlines currently have plenty of room for drug cargo--and even appear to be catering to the drug business, as we've reported--they are cutting capacity. As the improving economy re-energizes global commerce in all industries, drug space on aircraft may become hard to find, says Kevin O'Donnell, a director at Tegrant Corp., in Pharmaceutical Commerce magazine.

A dozen vaccines are nearing approval for distribution in developing and middle-income countries, according to the Partnership for Appropriate Technology in Healthcare. And vaccine shipments are getting fatter: PATH projects a five-fold increase in cubic volume for three of these, thanks to the packaging of fewer doses per vial to minimize spoilage. In addition, temperature-sensitive biologics as a whole are growing nicely and projected to represent half of drug approvals by 2015.

These and other elements, when combined, will cause a cargo crunch. "If the airlines move too cautiously, capacity will become an issue," writes O'Donnell. "Even though pharmaceutical freight has a higher priority index than general cargo, there is a real potential that demand could exceed available capacity."

A transport alternative to consider is sea shipment, he says. "While the risk of putting multi-million dollar shipments of brand equity on the waves is not a consideration most pharma companies have entertained in the past, developing technologies for refrigerated sea containers and logistics" makes it worth a second look, according to O'Donnell. He provides a biopharma to-do list to help manufacturers prepare for the coming crunch.

- here's the article

Related Articles:
Cold chain calls to suffering airlines
Booming vax market will more than double by 2014

Vax makers hit a roadblock, slowing global supply
Biologics to top pharma sales by 2014


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FiercePharma Manufacturing Email Newsletter:

More stories about cold chain   vaccine manufacturing